Read this topic

Clinical Psychopharmacology · Paper A

Area under the curve

The idea

AUC is the running total of everything a drug did to your body between the dose and full elimination — not the highest spike, not how fast it disappeared, but the whole area it swept out. Two very different-looking concentration curves can hand a patient the exact same total exposure, and two identical-looking peaks can hide very different totals underneath them.

How it works

AUC is the mathematical integral of the plasma concentration–time curve (∫C dt) — a single number, in units of concentration x time (e.g. mg·h/L), that sums total systemic drug exposure regardless of the curve's shape.
For a single intravenous dose, AUC = Dose / Clearance; for an oral dose, AUC = (Bioavailability x Dose) / Clearance — clearance is the parameter that, for any fixed dose, sets AUC directly.
Bioavailability (F) is calculated FROM two AUC measurements: F = AUC(oral) / AUC(intravenous), since an IV dose is defined as 100% bioavailable.
AUC is dissociable from Cmax (the single peak concentration) and Tmax (the time the peak is reached) — both describe the ABSORPTION phase and its rate, while AUC describes the WHOLE exposure; a modified-release formulation is deliberately engineered to lower Cmax and delay Tmax while preserving AUC.
AUC is dissociable from elimination half-life (t½) and the elimination rate constant (k) — both describe how fast concentration falls, not how much total exposure occurred; half-life can stay unchanged even when AUC changes, if clearance and volume of distribution shift together.
Anything that changes clearance changes AUC in the opposite direction: cytochrome P450 enzyme INHIBITION (e.g. fluvoxamine on CYP1A2) cuts clearance and RAISES AUC within days, risking toxicity; enzyme INDUCTION (e.g. carbamazepine, tobacco smoke on CYP1A2) raises clearance and LOWERS AUC over days to weeks, risking therapeutic failure.
AUC underlies regulatory bioequivalence testing (comparing a generic against the original formulation) and, in clinical psychopharmacology, the exposure-based logic behind therapeutic drug monitoring for narrow-therapeutic-index drugs such as lithium and clozapine, even where practice monitors a proxy trough level rather than calculating AUC directly.

How to spot it

A vignette describing 'total exposure' or 'the area under the concentration-time curve' without further qualification is describing AUC, not any single time-point reading.
A vignette comparing two formulations with different peak heights or different times-to-peak, but describing their total 24-hour exposure as equivalent, is testing the AUC vs Cmax/Tmax dissociation — the answer about 'what stayed the same' is AUC.
A vignette describing a new interacting drug that blocks a metabolising enzyme, followed by a RAPID (days) rise in plasma level and toxicity, is describing enzyme inhibition lowering clearance and raising AUC — not induction.
A vignette describing a drug or exposure withdrawn (smoking cessation, stopping an inducer) followed by a SLOW (one to two weeks) rise in level is describing the loss of enzyme induction, not new inhibition.
A vignette giving two AUC values (one IV, one oral) and asking for 'the fraction absorbed' or 'the proportion reaching the circulation unchanged' is asking for bioavailability, calculated as the ratio of the two AUCs — not for either AUC value alone.

Tell it apart

AUC (total exposure, the whole area) vs Cmax (the single highest point) — two formulations can share an identical AUC while having very different Cmax, which is exactly how modified-release products are designed.
AUC vs Tmax (when the peak occurs) — Tmax describes absorption speed only; total exposure can be identical whether the peak arrives at 30 minutes or 6 hours.
AUC vs elimination half-life (t½) — half-life is a RATE of decline (0.693 x Vd/Clearance), not a total; it can be unchanged while AUC changes substantially if clearance and volume of distribution move together.
AUC vs clearance — clearance is the MECHANISM (AUC = Dose/Clearance); AUC is the RESULT. A question about 'what fell to cause exposure to rise' wants clearance, not AUC.
AUC vs bioavailability (F) — F is a ratio built FROM two AUC values (oral ÷ intravenous), not a measure of total exposure itself; a drug can have low bioavailability yet still reach an adequate AUC if the oral dose is raised.
AUC vs volume of distribution (Vd) — Vd describes how far a drug spreads into tissue versus staying in plasma and drives loading-dose calculations; it carries no direct exposure-over-time information.
Enzyme inhibition (AUC rises, within a dose or two) vs enzyme induction (AUC falls, over days to weeks) — same clearance mechanism, opposite direction and opposite timescale.

Watch for

⚠️ Assuming AUC means 'the peak level' — it does not; Cmax is the peak, AUC is the total area, and the two are deliberately dissociated by modified-release formulations.
Naming AUC when a question is really asking for the MECHANISM that changed it (clearance falling or rising) — AUC is the consequence, not the cause.
Assuming a drug's half-life must change whenever its AUC changes — it does not, if clearance and volume of distribution shift in the same proportion, since half-life depends on their ratio.
Confusing bioavailability (a ratio, F = AUC oral/AUC IV) with AUC itself — a low-bioavailability drug is not automatically a low-AUC drug once the oral dose is corrected for it.
Assuming enzyme induction and inhibition both act the same way — inhibition is fast (a dose or two) and raises AUC/toxicity risk; induction is slow (days to weeks, new protein has to be built) and lowers AUC/relapse risk. Mixing up the direction or the timescale is the classic trap.
Treating a low Cmax as evidence of poor total exposure — a well-designed modified-release product deliberately lowers Cmax while keeping AUC (and therefore efficacy) essentially unchanged.

Use it again

First askis the stem describing a TOTAL (summed across the whole curve) or a SINGLE POINT (a peak, a time, a rate)? Only the first is AUC.
If two values are being divided into each other (an oral reading over an intravenous reading), the question is building bioavailability FROM AUC, not asking for AUC itself.
If clearance is stated to have changed, remember AUC = Dose/Clearance and reason the direction directly: clearance down means AUC up, clearance up means AUC down — do not guess.
If half-life or the elimination rate constant is mentioned alongside a change in AUC, check whether clearance AND volume of distribution have both changed together before assuming half-life must have moved too — it may not have.
If a drug interaction is described, decide inhibition vs induction from the TIMESCALE given (days-to-two-weeks favours induction lost or gained; a dose or two favours inhibition) before deciding which direction AUC has moved.

In detail

Hook — the parcel that took two different roads

Picture two identical parcels sent to the same address. One goes by an overnight courier that arrives in a single rushed dash, dropped hard on the doorstep and gone from the van almost immediately. The other goes by regular post, drifting through the system for a full day before it settles on the same doorstep. If you only checked the two vans at the moment of highest speed, you would say they were nothing alike. But if you asked "how much parcel actually got delivered, added up across the whole day", the answer might be identical. That second question — the total, not the peak — is what area under the curve, AUC (the standard shorthand used everywhere in pharmacology), is built to answer for a drug moving through the body.

Plain definition

AUC is the total amount of drug your body is exposed to after a dose, summed across every moment from the dose until the drug is gone. Picture a graph with time along the bottom and the drug's concentration in your blood up the side; the level rises as the drug is absorbed, peaks, then falls as your body clears it away. AUC is the space shaded in underneath that whole line — not the height of the peak, not how long the line took to fall, just the total area the curve encloses. It is measured in units that multiply concentration by time (for example, milligrams per litre multiplied by hours), because it genuinely is a "how much, for how long" number rather than a plain concentration reading.

The critical caveat — a total, not a moment

Here is the trap almost everyone falls into at first: assuming AUC means "the highest level reached." It does not. That job belongs to a different parameter, Cmax (maximum concentration) — the single tallest point on the graph. AUC and Cmax are deliberately dissociable, and drug manufacturers exploit that on purpose: a slow-release tablet is built to spread the same total dose out over more hours, which lowers the peak (Cmax) and delays it (Tmax, the time the peak is reached) while keeping the total area (AUC) almost exactly the same as the ordinary tablet. A lower peak does not mean a smaller total exposure — it can mean identical exposure, delivered more gently.

First principles — why one number can summarise a whole curve

Your body treats every dose of a drug the same way in outline: it absorbs some of it, spreads it around, and then clears it out, mostly through the liver and kidneys. Two numbers control almost everything that happens to the concentration once it is in your blood: (how much drug is removed per unit time) and (how large a "container" the drug is spreading into).

AUC falls straight out of the first of those two numbers. For a drug given directly into a vein, the relationship is exact: AUC = Dose ÷ . If a fixed dose goes in and the body clears it more slowly, the total area under the curve must be bigger, because the same amount of drug now lingers in the blood for longer before being swept away. Nothing else about the curve's shape matters for that calculation — only the dose and the clearance.

, the fraction of a dose that ever reaches your bloodstream in the first place, is built out of two AUC measurements rather than being a separate reading of its own: F (bioavailability) = AUC(oral) ÷ AUC(intravenous), because a dose given straight into a vein is defined as 100% available — none of it can be lost to poor absorption or to (the liver breaking some of an oral dose down before it ever reaches the general circulation).

Structured walk-through — a worked example, both formulas

Suppose a 100 mg dose of a drug is given by injection directly into a vein, and the resulting AUC, measured from a series of blood samples, comes out at 50 mg·h/L. From AUC = Dose ÷ , you can rearrange to find clearance: Clearance = Dose ÷ AUC = 100 mg ÷ 50 mg·h/L = 2 L/h. That single number — two litres of blood effectively cleared of the drug every hour — is now known for this patient.

Now suppose the same patient is given the identical 100 mg dose as a tablet instead, and this time the AUC comes out lower, at 25 mg·h/L, because some of the oral dose never made it past in the liver. is then F = AUC(oral) ÷ AUC(intravenous) = 25 ÷ 50 = 0.5, or 50%. Half the oral dose reached the bloodstream unchanged; the other half was lost before it ever counted. Both numbers — and bioavailability — came directly out of AUC measurements, which is exactly why AUC sits at the centre of pharmacokinetics rather than beside it.

Look-alikes & differentials

Looks like AUC	How to tell it apart
Cmax (peak concentration)	The single highest point, not the total area; a lower Cmax can hide an identical AUC
Tmax (time to peak)	Describes speed of absorption only, carries no total-exposure information
Elimination (t½)	A RATE of decline (time to fall by half); can stay unchanged even when AUC changes
	The MECHANISM that sets AUC (AUC = Dose ÷ Clearance) — the cause, not the total itself
(F)	A ratio calculated FROM two AUC values, not a fresh exposure measurement

Diagnosis — how a real AUC is actually measured

There is no single blood test that hands you an AUC directly; it is calculated, not read off a monitor. A real AUC is established by taking multiple blood samples at set time points after a dose — enough to trace the rise, the peak and the fall of the concentration-time curve — and then integrating (mathematically summing) the area under the resulting line, often using a method called the trapezoidal rule, which approximates the curve as a series of thin trapezoid-shaped strips and adds their areas together.

This full sampling schedule is standard in drug-development and bioequivalence studies, where a generic formulation's AUC and Cmax must both fall within an accepted range of the original product's values before regulators approve it as equivalent. On an ordinary ward, taking that many samples is rarely practical, so routine therapeutic drug monitoring instead measures a single proxy value — most often a trough level (the lowest concentration, taken just before the next dose) — and interprets a change in that trough as a signal that the underlying AUC has probably shifted, rather than calculating AUC itself.

Management — what changes on the ward when AUC is what's moving

For a drug with a narrow therapeutic index (a small gap between an effective dose and a toxic one), managing a changed AUC means finding and treating the mechanism, not just the number. Clozapine, monitored by trough plasma levels under guidance in the Maudsley Prescribing Guidelines in Psychiatry, is the clearest psychiatric example: starting fluvoxamine (a potent inhibitor of the CYP1A2 enzyme that clears clozapine) can raise a patient's clozapine AUC several-fold within days, by blocking existing enzyme molecules outright. The practical response is to anticipate the interaction, monitor levels closely, and reduce the dose.

Stopping smoking has the opposite direction on a slower clock. Tobacco smoke's hydrocarbons induce (increase the supply of) that same CYP1A2 enzyme, so a smoker admitted to a smoke-free ward loses the extra enzyme gradually, over one to two weeks, as the excess protein is worn away rather than switched off. Clozapine's falls, its AUC climbs, and the response is a pre-emptive level and a planned dose reduction rather than waiting for toxicity to appear.

Lithium, cleared by the kidneys rather than the liver, follows the same underlying logic even though nobody calculates its AUC on a ward: anything that reduces renal — dehydration, or a newly started ACE inhibitor or NSAID — raises lithium's effective exposure on an unchanged dose, which is exactly why a trough lithium level is checked whenever a patient's fluid balance or co-prescribed medications change.

Exam pearl

Whenever a stem describes a "total exposure" figure, or compares two formulations that reach different peaks but claims their overall exposure is equivalent, the parameter being tested is AUC — not Cmax, not . And whenever a level rises within days of starting a new drug, think (fast, existing enzyme blocked); whenever it drifts over one to two weeks after a drug or habit is stopped, think fading. Before you move on: could you explain to a friend why a slow-release tablet can have a much lower peak level than the ordinary version, and still deliver exactly the same total dose over the day?

In one line

AUC is the total area under the whole concentration-time curve — the running total of a patient's real exposure to a drug — which is why it, not the peak or the speed of the fall, is what changes whenever changes and what regulators check when they compare one formulation against another.